Reportlinker Adds Renal Cell Carcimona Drug Discoveries - what the future holds

Aug 31, 2010, 10:58 ET from Reportlinker

NEW YORK, Aug. 31 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Renal Cell Carcimona Drug Discoveries - what the future holds

http://www.reportlinker.com/p0192417/Renal-Cell-Carcimona-Drug-Discoveries---what-the-future-holds.html

This is a very exciting time in the treatment of renal cell carcinoma (RCC)...

With the advent of the new targeted therapies there has been a complete shift in paradigm. Treatment options for patients with advanced disease have improved dramatically; until recently there was limited choice and therapies were poorly tolerated, with relatively low response rates. Patients now face multiple options with improved safety and efficacy, and there are plenty of further therapies in the pipeline. The overall prognosis has changed for these patients and survival is now much longer.

While the RCC market has traditionally constituted a relatively small segment of the oncology market, it has more recently attracted considerable R&D investment from big pharma, biotechnology companies and specialty pharma. Older immunotherapy regimens have now been replaced as the standard of care by the newer targeted therapies launched in recent years, namely Pfizer's Sutent (sunitinib), Bayer/Onyx' Nexavar (sorafenib), Roche's Avastin (bevacizumab) and Pfizer's Torisel (temsirolimus). Since the launch of these agents in 2005/2006, the RCC market has become a rapidly-growing segment, with almost US$2.2 billion spent on branded drugs in 2008.

Significant opportunities still exist for products to expand within this marketplace. A large percentage of patients are not currently treated with drug therapies and are not cured by surgery alone; patients with localised and locally-advanced disease represent a significant patient population that may be suitable for adjuvant therapy with targeted therapies. Established agents such as Sutent, Nexavar and Avastin are being investigated in the adjuvant setting, along with new therapies including Wilex' Rencarex (girentuximab), currently in Phase III trials. In addition, many patients do not respond to current therapies, and more effective product introductions and greater use of combination therapies will address this clinical need for patients with metastatic RCC.

This report forecasts that sales of RCC treatments will increase substantially to almost US$6.5 billion in 2015, with a compound annual growth rate of 16.8%

The number of patients by value in the US, Europe (top five countries) and Japan will increase by 35.7% by 2015 (from around 613,000 in 2008 to approximately 832,000 in 2015). We estimate that approximately 18% of the RCC patient population currently receives drug therapy. By 2015, we expect a higher percentage of patients to receive treatment, reflecting an increase in the number of treatment options, improvements in drug efficacy and the use of drug therapy earlier in the course of the disease.

Why this sector is important: positive drivers

Better US diagnosis rates: Over 30% of RCC cases in the US are diagnosed at Stages III or IV, an area of high unmet clinical need.

The need for improved efficacy: Around 50% of early-stage patients are not cured by surgery and around 80% of patients with advanced disease fail to respond to approved therapies.

Alternative drug administration: Current immunotherapy requires frequent administration, intramuscularly or intravenously, and the advent of longer-acting oral products will be welcomed by clinicians and patients alike.

More therapy choice: New treatments will gain broader indications in the treatment of RCC eg in the adjuvant or neoadjuvant setting at earlier stages of disease due to their proven track record of safety and efficacy.

Improved funding: Increased accessibility to cancer drugs via Medicare reform, Medicaid coverage and the European and Japanese regulatory health authorities.

The shape of the RCC sector in 2008...

In 2008, the RCC market was driven by sales of new targeted agents, namely Pfizer's Sutent (sunitinib) and Bayer/Onyx' Nexavar (sorafenib) as the clear leaders, followed by Roche's Avastin (bevacizumab) and Pfizer's Torisel (temsirolimus). Together these therapies secured sales of almost US$1.8 billion. Just five major players competed for a share of the RCC market. The introduction of targeted therapies in 2005/2006 has seen Pfizer and Bayer/Onyx come from nowhere to now dominate with a combined 67% market share.

...and in 2015

The total RCC sales for branded products will increase substantially from almost US$2.2 billion in 2008, to almost US$6.5 billion in 2015, with a compound annual growth rate of 16.8%. Sales will be driven by the new targeted therapies which will account for sales of around US$6.1 billion in 2015, with Pfizer's Sutent, Bayer/Onyx' Nexavar, Roche's Avastin and GlaxoSmithKline's Armala/Votrient responsible for approximately US$4.5 billion of this. There are four current Phase III products which have the potential to reach the market by 2015, including Wilex' Rencarex.

EXECUTIVE SUMMARY

WHAT IS RENAL CELL CARCINOMA?

Stages of the Disease

Risk Factors

PATIENT STATISTICS

Incidence and Mortality

Survival and Stage at Diagnosis

PATIENT MODEL

DRUG GROWTH DRIVERS

DRUG GROWTH RISKS/DAMPENERS

CURRENT TREATMENTS

Leading Brands

Current Products' Patent Exposure

THE CURRENT RENAL CELL CARCINOMA MARKET

PLAYERS AND PRODUCTS IN 2008

Geographic Areas

RESEARCH & DEVELOPMENT OF RCC DRUGS

WHAT THE FUTURE HOLDS

GLOBAL SALES FORECASTS TO 2015

Model Assumptions

PLAYERS AND PRODUCTS IN 2015

COMPETITOR RATIO ANALYSIS

Competitor Ratio Analysis Criteria

COMPETITOR RATIO ANALYSIS - PRODUCTS

COMPETITOR RATIO ANALYSIS - COMPANIES

Winners and Losers

Winners

Losers

Analysis of Leading Brands

Targeted Therapies

Armala/Votrient

Avastin

Afinitor

Nexavar

Oncophage

Sutent

Torisel

Immunotherapies

Intron A

Roferon-A

Pegasys

PEG-Intron

Proleukin

Analysis Of Products Under Development

Phase III Projects

Anyara

Axitinib

Rencarex

Tivozanib

Phase II Projects

Archexin

AS1411

Foretinib

IMA901

Interleukin-21

Perifosine

Regorafenib

Talactoferrin alpha

Phase I/II Projects

AGS-003

ImmuFact

DISCONTINUATION OF DRUGS

APPENDIX 1

Appendix 2

Appendix 3

Phase Transition Probability

RCC GLOSSARY

Index of Tables

RCC Stages

RCC Stage at Diagnosis, US

Five-year Relative Survival Rates by Stage at Diagnosis, 1996-2004

RCC US Population Model, 2008-2015

RCC European Population Model, 2008-2015

RCC Japanese Population Model, 2008-2015

RCC Population Models, Top Seven Countries, 2008-2015

Worldwide RCC Population Model, 2008-2015

Summary of Standard Treatment Options for RCC

Comparison of Leading RCC Agents

Comparison of Recently-Launched RCC Agents

Patent Exposure of Leading Brands

Drugs in Development to Treat RCC

Timeline of Selected RCC Development Projects

Sales Forecasts of Current and Future Leading RCC Drugs (US$ millions)

Key RCC Drugs Analysed

Summary of Key Companies in the RCC Market by 2015

Axitinib Treatment-Related Adverse Events

Drugs Discontinued from Clinical Development in RCC

Fuhrman Grading System for Renal Cell Carcinoma

TNM Staging of Renal Cell Carcinoma

AJCC Stage Groupings

Probability of Launch

Index of Charts

Schematic of Kidney

RCC Incidence by Age at Diagnosis, UK

Worldwide Incidence of the Major Cancers, 2008

International Variation in RCC Incidence Rates, 2002

RCC Incidence Rates for Selected Countries, 2002

US Kidney Cancer Incidence Rates by Age, 1992-2006

US Age-Adjusted Kidney Cancer Incidence Rates by Race/Ethnicity, 1992-2006

US Kidney Cancer Mortality Rates by Age, 1992-2006

Projected % Change in Age-Standardised RCC Mortality in the US, Europe and Japan, 2002-2015

RCC Mortality Rates for Selected Countries, 2002

RCC Incidence, Top Seven Countries, 2008-2015

RCC Mortality, Top Seven Countries, 2008-2015

Market Share (Branded Sales) of Top Five Cancers, 2008

Therapy Sales Split for Major Branded RCC Products, 2008

Market Share for Major Branded RCC Products, 2008

Market Share for Major RCC Players, 2008

Sales Forecasts of RCC Therapies Launched in 2008 (US$ millions)

Sales Forecasts of RCC Therapies Launched from 2009 (US$ millions)

Therapy Sales Split for Major Branded RCC Products, 2015

Market Share for Major Branded RCC Products, 2015

Market Share for Major RCC Players, 2015

Competitor Ratio Analysis Scores by Product

Major RCC Products, 2008

Analysis of RCC Products based on Drug Class, 2015

Table of Contents

©Espicom Business Intelligence vi February 2010

Section Name Renal Cell Carcinoma Drug Discoveries

Analysis of RCC Products based on Delivery, 2015

Competitor Ratio Analysis of RCC Products Based on Company, 2015

Votrient/Armala RCC Sales (2009E-2015E)

Avastin Mode of Action

Avastin RCC Sales (2008E-2015E)

Afinitor Mode of Action

Afinitor RCC Sales (2009E-2015E)

Nexavar's Dual Mode of Action

Nexavar RCC Sales (2008E-2015E)

Oncophage RCC Sales (2009E-2015E)

Sutent Mode of Action

Sutent RCC Sales (2008E-2015E)

Torisel's Mode of Action

Torisel RCC Sales (2008E-2015E)

Intron A RCC Sales (2008E-2015E)

Roferon-A RCC Sales (2008E-2015E)

Pegasys RCC Sales (2008E-2015E)

PEG-Intron RCC Sales (2008E-2015E)

Proleukin Mode of Action

Proleukin RCC Sales (2008E-2015E)

Anyara's Mode of Action

Anyara RCC Sales (2013E-2015E)

Axitinib RCC Sales (2012E-2015E)

Rencarex' Mode of Action

Tivozanib RCC Sales (2013E-2015E)

Signalling Pathways Affected by Archexin

AS1411 Proposed Mechanism of Action

Mode of Action of IMA901

IL-21 Initiating Antibody-mediated Tumour Lysis

Perifosine's Mechanism of Action

Talactoferrin's Mechanism of Action in Cancer.

To order this report:

Drug Discovery and Development Industry: Renal Cell Carcimona Drug Discoveries - what the future holds

Drug Discovery and Development Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com